Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients
The New York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry’s commitment to the program. Today, we’re correcting the record. Fact: Manufacturers are still giving the 340B discounts, as required by law, to “covered entities” – more than 12,700 …